Goodsurance
ES

Drug prices & Part D

Medicare Insulin Costs Cut in Half Since 2020, KFF Report Finds

Per-prescription out-of-pocket insulin spending for Part D enrollees without low-income help fell from 54 dollars in 2020 to 25 dollars in 2024, driven by manufacturer pricing changes and a federal monthly cap that took effect in 2023.

By the Goodsurance editorial teamNovember 21, 2026

A KFF analysis of Medicare prescription drug claims finds that out-of-pocket spending per insulin prescription fell by more than half for Part D enrollees who do not receive low-income subsidies, dropping from 54 dollars in 2020 to 25 dollars in 2024. Total aggregate out-of-pocket insulin spending across all Part D enrollees declined from 971 million dollars in 2020 to 506 million dollars in 2024.

The decline reflects two waves of change. First, in 2021, the Part D Senior Savings Model began capping monthly copays for selected insulin products at 35 dollars in participating plans, and total out-of-pocket spending fell roughly 23 percent in that first year, to about 745 million dollars. Second, beginning in 2023, the Inflation Reduction Act required all Part D plans to cap monthly insulin cost-sharing at no more than 35 dollars, extending the protection to every covered insulin product across all plans regardless of which plan an enrollee chose.

Medicare insulin costs fell from 54 dollars to 25 dollars per prescription since 2020. Here is what drove the change.

Enrollees who qualify for Extra Help, the Part D Low-Income Subsidy, already had near-zero insulin cost-sharing before these changes. The largest gains in affordability went to the broader population of Part D enrollees who had faced the highest out-of-pocket exposure.

The analysis draws from prescription drug event claims in a 20 percent sample of Medicare beneficiaries held in the CMS Chronic Conditions Data Warehouse.

The findings arrive as Medicare open enrollment continues through December 7, 2026. For 2027, a new 2,400-dollar annual out-of-pocket cap on all Part D drug spending also takes effect. The 35-dollar monthly insulin cap continues to apply in every Part D plan.

In plain words

KFF is a group that studies health care costs. It looked at Medicare drug plan records from 2020 to 2024. People on Medicare without extra help now pay much less for insulin. Each prescription used to cost about 54 dollars out of pocket. By 2024, that fell to 25 dollars. Total insulin spending by all Medicare drug plan members dropped from 971 million dollars to 506 million dollars over those four years.

Two things helped. Starting in 2021, some Medicare drug plans began capping monthly insulin costs at 35 dollars. Then in 2023, a federal law made that 35-dollar monthly limit apply to every Medicare drug plan. People who already get extra help with their Medicare costs had been paying very little before these changes.

Open enrollment runs through December 7. For 2027, there is also a new cap on total yearly drug spending. The 35-dollar monthly insulin limit stays in place for all Medicare drug plans.

Source: KFF
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Medicare Part D Rarely Covers the OTC Naloxone Nasal Spray. Medicaid Usually Does.

A new Government Accountability Office report finds that most Part D plans stopped covering the over-the-counter naloxone nasal spray after it no longer required a prescription, while Medicaid covers the same product at little or no cost to enrollees.

November 16, 2026

Drug prices & Part D

Biotech Industry Group Files Second Lawsuit to Block Medicare's GLOBE Drug Pricing Model

BIO and two California biotech groups sued CMS on November 6, arguing the program exceeds legal authority. A first challenge from PhRMA filed in October remains pending.

November 12, 2026

Drug prices & Part D

KFF: Medicare's 340B Drug Payment Cut Reduces Revenue for Safety-Net Hospitals While Raising It for For-Profit Ones

Now that the 2027 outpatient rule is final, a KFF analysis finds the 340B reimbursement cut falls hardest on hospitals that serve low-income patients, while for-profit hospitals see a net gain.

November 11, 2026

Drug prices & Part D

Medicare Drug Price Negotiation Rules Are Now Permanent, Federal Register Shows

The CMS-4215-F final rule, published today, converts the negotiation program from administrative guidance into binding federal regulation for every drug-price cycle starting in 2029, and requires Part D plans to cover negotiated-price drugs on their formularies.

November 9, 2026

Drug prices & Part D

Third Medicare Drug Negotiation Cycle Closes, Including Part B Doctor-Office Drugs for the First Time

The formal negotiation period for 15 drugs ended November 1; CMS must publish any agreed-upon maximum fair prices by November 30, including the first-ever negotiated prices for drugs given in doctors' offices.

November 1, 2026

Drug prices & Part D

Average Medicare Part D Stand-Alone Premium Projected to Rise 50 Percent for 2027, KFF Finds

A KFF analysis published today finds the average monthly premium for stand-alone Part D drug plans is on track to climb from 34 dollars to 51 dollars for 2027, with deductibles also rising sharply, for enrollees who do not switch plans before December 7.

October 30, 2026